Regular ArticleDoes the Interval from Primary Surgery to Chemotherapy Influence Progression-Free Survival in Ovarian Cancer?
References (9)
- et al.
Randomized study of 2 doses of cisplatin with cyclophosphamide in epithelial ovarian cancer
Lancet
(1992) - Ries, L, AG, Eisner, M, P, Kosary, C, L, Hankey, B, F, Miller, B, A, Clegg, L, Edwards, B, K (eds). SEER Cancer...
- et al.
Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials
Br J Cancer
(1995) - et al.
Docetaxel–carboplatin as first line chemotherapy for epithelial ovarian cancer
Br J Cancer
(2001)
There are more references available in the full text version of this article.
Cited by (45)
Return to intended oncologic therapy: a potentially valuable endpoint for perioperative research in cancer patients?
2020, British Journal of AnaesthesiaInterval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer
2018, Gynecologic OncologyCitation Excerpt :These differences illustrate the heterogeneity of studied populations and therefore may explain the inconsistent outcomes. In addition, TTC intervals were based on either IQR [13–15], median TTC [6, 7, 18, 20], or various weeks [16, 17, 19, 21–23], which also contributes to the conflicting results. In our study, we chose for IQR and compared the outliers (lowest and highest IQR groups) with the intermediate group (mean IQR) as we were interested if either early or late start influenced clinical outcomes.
Chemotherapy delay after primary debulking surgery for ovarian cancer
2017, Gynecologic Oncology
- 1
To whom correspondence should be addressed at present address: University Hospital of North Tees, Hardwick, Stockton on Tees, TS19 8PE, United Kingdom. Fax: +44 7092 173892. E-mail: [email protected].
Copyright © 2002 Elsevier Science (USA). All rights reserved.